Boothbay Fund Management’s Soleno Therapeutics SLNO Stock Holding History

Boothbay Fund Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-17,700	Closed	-$820K	–	2445
2025 Q4	$820K	Sell	17,700 -36,100	-67%	-$1.98M	0.01%	883
2025 Q3	$3.64M	Sell	53,800 -39,600	-42%	-$2.94M	0.05%	410
2025 Q2	$7.83M	Buy	93,400 +52,100	+126%	+$3.9M	0.15%	181
2025 Q1	$2.95M	Buy	41,300 +19,700	+91%	+$959K	0.08%	342
2024 Q4	$971K	Buy	+21,600	New	+$1.12M	0.02%	648
2024 Q3	–	Sell	-15,900	Closed	-$649K	–	1903
2024 Q2	$649K	Buy	+15,900	New	+$674K	0.02%	904
2020 Q3	–	Sell	-99	Closed	-$329K	–	1200
2020 Q2	$329K	Buy	+99	New	+$4.29K	0.02%	677

Other funds holding SLNO

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

KCM

Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return

Boothbay Fund Management's SLNO Position: Q1 2026 in Review

Boothbay Fund Management increased its Soleno Therapeutics (SLNO) stake by 184% in Q1 2026, buying an estimated $3.16M and bringing the position to 124,519 shares worth $4.17M. The position accounts for 0.05% of the portfolio, ranked #367.

Boothbay Fund Management first reported a position in SLNO in Q2 2020 and has held it in 17 quarters since. The position peaked at $5.65M in Q1 2024. 225 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

Boothbay Fund Management held 124,519 shares of Soleno Therapeutics worth $4.17M as of Q1 2026.
Boothbay Fund Management bought 80,657 Soleno Therapeutics shares in Q1 2026, an estimated $3.16M.
Soleno Therapeutics made up 0.05% of Boothbay Fund Management's portfolio in Q1 2026, its #367 holding.
Boothbay Fund Management first reported a position in Soleno Therapeutics in Q2 2020 and has held it in 17 quarters since.
Boothbay Fund Management's Soleno Therapeutics position peaked at $5.65M in Q1 2024.
225 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.